Skip to main content

Table 2 Human Breast Cancer Models ABBV-176; N = 3 Screen Study

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Model ID

PRLR Density vs MCF7

Drug Dosesa

ABBV-176 Efficacyb

ER/PR/HER2 BRCA Status

CTG-1124

0.15

0.2

High (84%)

ER+/PR+

BRCA 1 def

CTG-0012

0.75

0.5

High (90%)

TNBC

BRCA 1 def

CTG-0869

0.8

0.5

High (93%)

TNBC

BRCA 1 mut

CTG-0670

1.64

0.5

High (91%)

TNBC

BRCA 1 def, BRCA 2 mut

CTG-0033c

2.06

0.2

High (79%)

HER2+

BRCA n.d.

CTG-1171

0.42

0.2

High (82%)

TNBC

BRCA 1, 2 mut

CTG-1019

0.37

0.2

High (83%)

TNBC

BRCA 1, 2 mut

CTG-1242

3.83

0.2

High (83%)

TNBC

BRCA n.d.

CTG-0052

0.46

0.2

Moderate (59%)

TNBC

BRCA wild type

CTG-0017

0.27

0.2

Moderate (62%)

TNBC

BRCA 1, 2 mut

CTG-1520

0.56

0.5

Low (48%)

TNBC

BRCA wild type

  1. BRCA breast cancer DNA associated repair gene, def deficient, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IP intraperitoneal, mut mutation, n.d. not determined, PR progesterone receptor, TGI tumor growth inhibition, TNBC triple negative breast cancer
  2. aDoses were administered IP Q7D × 3, at the dose level indicated in mg/kg
  3. bLow = 25–50% TGI, Moderate = 50–75% TGI, High > 75% TGI compared to control PBD ADC treated group (p < 0.0001)
  4. cThis study was performed with larger size treatment groups (N = 6)